Interestingly, the pharmacodynamic analysis revealed that only 58% of AML patients treated with lestaurtinib reached a sufficient FLT3 inhibition (less than 15% of its baseline activity) by day 15 of therapy, and the level of inhibition correlates with the remission rate [55]. The gene discussed is FLT3; the disease is acute myeloid leukemia.